| 1 |
Which of the following best describes the concept of "beat perception" as it relates to the auditory capabilities of newborn infants?
|
The ability to vocalize in response to auditory stimuli. |
|
Beat perception helps us understand and detect a pulse/beat, which in this case, could indicate something such as a newborn infants heartbeat. We all know that newborn infants dont have refined sensitivity as us older children or adults, but basic beat perception such as the ability to detect something from a noise/sound could already indicate basic auditory capabilities in newborn infants.
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
According to the research, what experimental method is used to differentiate beat perception from statistical learning in newborns?
|
Monitoring brain activity using EEG during auditory stimulation. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does the mismatch response (MMR) in EEG studies indicate about newborns' auditory processing?
|
Discomfort or displeasure in response to loud sounds. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
What does the term "statistical learning" refer to in the context of auditory processing in newborns?
|
Ability to understand spoken language. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
Which condition in the EEG study did NOT result in a differentiation between beat and offbeat responses in newborns?
|
Silence condition. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
Which neural mechanism is thought to underlie the synchronization of movement to a beat?
|
Sensory gating. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
How does beat perception in newborns relate to their later musical abilities?
|
It is fundamental for developing rhythmic coordination and timing. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What is the primary purpose of using EEG in studies of auditory processing in newborns?
|
To record brain responses to sounds. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
What does an isochronous condition in an auditory study typically involve?
|
A consistent temporal interval between sounds. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
Which auditory feature is NOT directly studied in the newborn auditory processing research?
|
Language comprehension. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What term is used to describe the appearance of scientific credibility used in the marketing of unproven cell-based therapies?
|
Tokens of scientific legitimacy |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
According to the article, which of the following is NOT a recognized reporting mechanism for adverse effects from cell and gene therapies?
|
EudraVigilance by the EMA |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What ethical consideration is primarily challenged by direct-to-consumer marketing of unproven cell and gene therapies?
|
Non-discrimination in therapy access |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What key feature differentiates proven CGT products from unproven ones according to regulatory standards?
|
All of the above |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
Which of the following is a risk associated with unproven CGT products highlighted in the article?
|
Potential for serious health risks |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
Which of the following is NOT a typical characteristic of unproven CGT products as discussed in the article?
|
Approval by major regulatory agencies |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
How do regulatory bodies like the FDA and EMA ensure the safety of CGT products?
|
By requiring rigorous pre-marketing clinical trials |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What is the primary goal of the ISCT's position on cell and gene therapies as mentioned in the article?
|
To support all types of cell and gene therapies equally |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What is a potential consequence for patients using unproven CGT products?
|
Risk of serious adverse effects |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What role does the ISCT play in the context of cell and gene therapies?
|
It opposes the premature commercialization of unproven therapies. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|